HealthDay on MSN19h
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ...
precisionmedicineonline23h
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...